DENVER, Colo. (247marketnews.com) – The market is once again rewarding investors who know where to look for catalysts, bioAffinity Technologies (NASDAQ:BIAF), NeOnc Technologies Holdings (NASDAQ:NTHI), Opus Genetics (NASDAQ:IRD), Eos Energy Enterprises (NASDAQ:EOSE) with Google (NASDAQ:GOOG), and Scorpio Gold (NASDAQ:SGLD) each have a distinctly different catalyst driving their narratives.
bioAffinity Technologies: CyPath Lung Moving Beyond Detection and into Survivorship
bioAffinity Technologies (NASDAQ:BIAF) is trying to turn CyPath Lung from an early-detection story into something potentially broader: a diagnostic tool that could play a role throughout the lung-cancer patient journey. The company announced September 1 that it is advancing the potential use of CyPath Lung for surveillance of patients who have completed curative-intent treatment. The opportunity is sizeable, with more than 680,000 Americans estimated to have a history of lung cancer as of January 1, 2025. The company argues that these patients can face a particularly difficult diagnostic problem when new or changing pulmonary nodules appear after treatment.
The clinical-commercial pitch is compelling because the problem is real: imaging may identify a suspicious nodule but cannot necessarily distinguish recurrent cancer from a new primary tumor or benign treatment-related changes. Vijay Gunuganti, MD, an oncologist with Texas Oncology, said: “Imaging alone cannot tell us if it is recurrent cancer, a new cancer, or benign post-treatment changes including fibrosis, scarring, and treatment-related inflammation.” He added that CyPath Lung could provide additional information without immediately sending a patient into an invasive procedure.
The important investor caveat is that the expansion into survivorship remains a potential application rather than a separately validated indication. bioAffinity cites prior clinical performance of 92% sensitivity, 87% specificity, 88% accuracy and 99% negative predictive value in high-risk patients with small indeterminate nodules, but the company explicitly states that those figures come from the detection setting and have not been separately validated for post-treatment surveillance. That distinction is critical: the commercial opportunity may be expanding, but the evidentiary burden expands with it.
Meanwhile, the commercial backdrop is getting more interesting. bioAffinity reported that CyPath Lung test volume increased 216% year over year in the second quarter of 2026, while an August distribution agreement with AvMEDICAL expanded the company's reach into federal healthcare channels, including VA medical centers. The company has also been developing a longitudinal clinical program. Against that progress sits a major risk: bioAffinity has been fighting a Nasdaq minimum-bid-price compliance issue after a prior reverse split, and its August 2026 1-for-15 reverse split was intended to address listing compliance.
NeOnc Technologies Holdings: NEO100 Turns Tiny Biotech into an FDA Catalyst Story
NeOnc (NASDAQ:NTHI) has one of the most dramatic clinical catalysts in this group. In August, the company reported positive topline Phase 2a results for intranasal NEO100 in recurrent or progressive IDH1-mutant Grade III and Grade IV glioma. Six-month progression-free survival came in at 48.9% versus a prespecified 20% benchmark, with a reported p-value of 0.0047. Median overall survival was reported at 26.09 months, while 86.7% of patients were alive at six months.
The next catalyst is regulatory rather than clinical. NeOnc plans to request a Type B meeting with the U.S. Food and Drug Administration to discuss a potential registrational development path for NEO100. CEO Amir F. Heshmatpour said: “Our priority now is to engage with the FDA and align on the most efficient path toward a registrational study.” That gives NTHI a defined event-driven pathway: the company now has to determine whether the FDA views the data and proposed development strategy as sufficient to justify a larger registration-oriented program.
The drug's delivery mechanism is part of the investment narrative. NEO100 is administered intranasally by patients at home, four times daily, and is designed to reach the brain along olfactory and trigeminal pathways while attempting to avoid conventional systemic exposure. NeOnc reported no major toxicities in the Phase 2a cohort, while five of 24 patients remained on treatment and one patient had reportedly remained progression-free for approximately 19 months. That combination, home administration, tolerability and apparent durability, is exactly the sort of profile that can generate outsized attention in a difficult cancer indication.
The Phase 2a population consisted of only 24 patients, the study was open-label and single-arm, and the 20% comparator was a prespecified benchmark rather than a randomized control group. NeOnc itself warns that comparisons with historical data are inherently limited and early-stage results may fail to replicate in larger controlled studies.
Opus Genetics: September 9 Could Put Gene-Therapy Pipeline on Center Stage
Opus Genetics (NASDAQ:IRD) is approaching a near-term binary-style catalyst of its own. The company announced Sthat it will present topline Cohort 1 data from the Phase 1/2 OPGx-BEST1 gene-therapy study on an investor webcast on September 9 at 8:00 a.m. ET. The company also plans to present the full dataset and additional analyses at upcoming ophthalmology conferences, including Euretina and Retina in Rio.
OPGx-BEST1 is designed to address BEST1-related inherited retinal diseases, including Best vitelliform macular dystrophy and autosomal recessive bestrophinopathy. The therapy uses an AAV vector to deliver a functional copy of the BEST1 gene to retinal pigment epithelial cells. The BIRD-1 study is an adaptive, open-label Phase 1/2 trial evaluating single-eye subretinal administration. The September presentation therefore matters because investors will get their first concentrated look at whether the clinical program is producing the kind of visual-function and safety signals that could support further development.
There is also a broader portfolio argument behind the event. Opus says its pipeline contains seven AAV-based programs, led by OPGx-LCA5 and OPGx-BEST1, with additional programs targeting RDH12, MERTK, RHO, CNGB1 and NMNAT1. In August, management said enrollment had been completed in its LCA5 registrational trial, with dosing expected to begin in the fourth quarter, while RDH12, MERTK and RHO were advancing toward clinical testing. The company also expects its current resources and potential future financing to support operations into 2029.
That financial runway is an important part of the bull case because gene therapy is capital intensive and development timelines are long. Opus has also added visibility through its inclusion in the Russell 3000, Russell 2000 and Russell Microcap indexes. CEO George Magrath previously said the company was rapidly advancing five gene therapy programs and that its cash position could support multiple clinical inflection points. Now the market gets a chance to judge the BEST1 data itself. For IRD, September 9 is the date that could turn a pipeline story into a data-driven story, for better or worse.
Eos Energy Enterprises: Google Just Added a Serious Commercial Validation to the Z3 Story
Eos Energy (NASDAQ:EOSE) is riding a different kind of catalyst: commercial validation at the intersection of artificial intelligence, grid demand and long-duration energy storage. On September 2, Eos, MN8 Energy and Google announced a West Virginia project combining 86 MW of solar, 10 MW/100 MWh of Eos Z3 zinc-based long-duration storage and 70 MW/280 MWh of lithium-ion storage. The project is designed to provide dispatchable clean capacity to the PJM grid, with solar expected to reach commercial operation in 2028 and the storage systems following in 2029 and 2030.
For EOSE shareholders, the Google relationship is the headline. Google will purchase the project's energy, capacity and clean-energy attributes, while Eos supplies its American-made zinc-based storage technology. The project also represents the first commercial-scale long-duration energy-storage deployment in West Virginia and the first project under the previously announced MN8-Eos Master Supply Agreement. Eos Chief Commercial Officer Nathan Kroeker said: “The grid needs more from every megawatt of new generation.”
The project lands after a substantial acceleration in Eos's commercial metrics. In its second-quarter report, the company said backlog had reached a record $807 million, up 25% sequentially, while quarterly revenue reached $68.8 million, a 351% year-over-year increase. Eos also said it had launched commercial production on its second battery line at Thorn Hill and was targeting further manufacturing efficiencies as production ramps. The company has subsequently moved toward consolidating manufacturing at Thorn Hill, a move management says is intended to improve efficiency, capacity utilization and margins.
The bull case is therefore increasingly about scale: Eos has a major backlog, new manufacturing capacity, strategic project financing through Frontier Power USA and now a high-profile customer relationship involving Google. But the financial numbers still show why this remains a speculative growth story. Eos reported a negative 71% gross margin in the second quarter and a $275.7 million net loss, even as revenue surged. CEO Joe Mastrangelo summarized the challenge bluntly: “Our focus now is converting that demand into profitable growth.” That sentence may be the single most important metric for EOSE going forward.
Scorpio Gold: Goldwedge Just Delivered the Kind of Drill Intercepts Traders Chase
Scorpio Gold (NASDAQ:SGLD) has a classic junior-mining catalyst: drill results that combine broad mineralization with high-grade intervals. The company reported that hole 26MN-115 at the Goldwedge target in Nevada returned 3.02 g/t gold over 48.92 meters, including an eye-catching 19.29 g/t over 5.24 meters. The same hole also returned 5.14 g/t over 10.15 meters at the faulted contact between the Zanzibar Formation and Manhattan Caldera Volcanics.
Hole 26MN-118 added another broad intercept, returning 1.19 g/t gold over 99.94 meters, including 5.13 g/t over 4.16 meters. Along the Zanzibar Trend, hole 26MN-116 produced 0.93 g/t over 22.16 meters and 0.84 g/t over 25.05 meters. The numbers matter because junior-gold investors are generally looking for some combination of grade, thickness, continuity and scale, and these results provide evidence for multiple parts of that equation.
Scorpio says the two Goldwedge holes were approximately 50-meter step-outs along the projected Reliance Fault from earlier high-grade mineralization. The company has now drilled 114 Phase Two holes totaling 32,585 meters, with assays reported for 107 holes covering 30,889 meters. Seven holes totaling 1,696 meters remain pending. That means the September 2 release is not an isolated hole story; it is another data point in a much larger drilling campaign.
CEO Zayn Kalyan described the latest results as evidence of both scale and grade, saying: “Manhattan keeps delivering on the two things that matter most in this market: scale and grade.” The company is also now trading its American Depositary Shares on Nasdaq under SGLD, following the September 1 debut. That combination, fresh Nasdaq visibility, a strong gold-market backdrop and another batch of meaningful drill results, gives SGLD one of the cleaner momentum narratives in this group.
About 24/7 Market News
In today's fast-moving markets, visibility is everything and 24/7 Market News (24/7) provides a powerful suite of investor relations and public relations solutions designed to elevate your company’s profile quickly and effectively. Whether you're an established name seeking broader awareness, or a micro-cap looking to break out of obscurity, 24/7 delivers targeted, high-impact coverage through timely news distribution, analyst report placements, featured editorials, and multi-channel amplification across financial platforms, social media, and investor communities. Our services help cut through the noise, attract institutional interest, drive exposure, and build long-term shareholder credibility, all while maintaining full SEC compliance and transparency. For Analyst Report coverage, custom IR campaigns, press release syndication, or other tailored investor and public relations solutions, contact sales@247mnn.com to discuss how 24/7 can help accelerate your company’s visibility and valuation trajectory.
This is a paid editorial communication intended for informational purposes only. 24/7 is compensated by NTHI to provide ongoing news coverage of expected upcoming catalysts and events as well as market outreach services. For further disclosure information, please click here. This should not be construed as financial or investment advice. Trading involves substantial risk; consult your financial advisor.
Important Editorial Note: 247 highlights companies approaching significant catalysts and inflection points. This report reflects information available at the time of publication. Since developments can occur rapidly, readers should independently verify current information and review all company filings and disclosures.
CONTACT:
24/7 Market News
Editor@247mnn.com
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company's ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Actual results could differ materially from those described in these forward-looking statements due to a number of factors, including without limitation, the Company's ability to continue as a going concern, general economic conditions, and other risk factors detailed in the Company's filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update such forward-looking statements except in accordance with applicable law.